Marco High-Cost Drugs integrates an extensive database of high-cost medications for Ovarian Cancer, enabling hospitals, payers and regulatory bodies to access updated information on approved indications, efficacy evidence, coverage criteria and therapeutic alternatives. The system supports evidence-based access and reimbursement decisions.
Some answers to questions we often receive
Marco High-Cost Drugs includes all high-cost oncology medications available for Ovarian Cancer: bevacizumab, olaparib, niraparib, rucaparib, mirvetuximab soravtansine and pembrolizumab in MSI-H, with their FDA and EMA approved indications, eligibility criteria (biomarkers, treatment line, performance status) and the evidence level supporting each indication per NCCN and ESMO guidelines.
Yes. Marco High-Cost Drugs includes for each Ovarian Cancer medication comparable therapeutic alternatives with efficacy comparisons (OS, PFS), toxicity profile and relative cost. This information supports therapeutic substitution decisions, vendor negotiations and institutional appropriate-use guideline design.
Marco High-Cost Drugs provides centralized procurement bodies and health ministries with the information needed for high-cost drug procurement in Ovarian Cancer: consolidated indications, estimated use volumes, available alternatives and comparative efficacy data supporting procurement justification and lab negotiations.
Marco High-Cost Drugs provides payers with evidence-based authorization criteria for high-cost medications in Ovarian Cancer, automatically verifying the consistency between the physician's request and approved indications. This reduces review times, standardizes decisions and minimizes off-label treatment authorizations.
The Marco team continuously monitors FDA, EMA and regional regulatory agency approvals for Ovarian Cancer. Every new approval, indication extension or label change is incorporated with precise indications, use criteria and clinical trial evidence that supported the approval.
Yes. Marco High-Cost Drugs includes approved biosimilars available for each biologic medication in Ovarian Cancer, with the comparability studies supporting interchangeability, approved indications for each biosimilar and local regulatory considerations for their use in hospitals and by payers.
PARP inhibitors have distinct indication criteria by BRCA and HRD status that generate confusion in coverage committees and avoidable delays.